Sep 2026· Immunotherapy· pp.
1-36
· 0 citations· 232 references
Medicine
TL;DR
The role of EGFRvIII in driving aggressive tumor growth is discussed and how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies are highlighted.
Abstract
Cancer is a leading cause of death globally, and traditional therapies including chemotherapy and radiotherapy are often constrained by systemic toxicity and lack of specificity. Thus, targeted therapies are the need of the hour to revolutionize cancer treatment by enhancing specificity and selectivity, and minimizing off-target effects. The epidermal growth factor receptor (EGFR) and its deletion mutant EGFRvIII exhibit pivotal roles in tumorigenesis, making them attractive targets across multiple cancers. Various targeted therapies, including small-molecule inhibitors, therapeutic antibodies, antibody-drug conjugates, and immunotherapies, are developed to target EGFR, EGFRvIII, and other clinically relevant EGFR mutations, namely L858R, C797S, and T790M. U.S. FDA has approved many of these agents as monotherapies or in conjunction with chemotherapy for treating lung, head and neck, and colorectal cancers; however, there are challenges. In this review, we discuss the role of EGFRvIII in driving aggressive tumor growth and highlight how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies. The ongoing evolution of these interventions holds promise for long-term responses, reduced toxicity, and enhanced patient survival. Literature related to EGFR- and EGFRvIII-based therapies was searched systematically in PubMed, MEDLINE, Scopus, ScienceDirect, and Google Scholar up to June 2026.
This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.
K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al.· Current Drug Discovery Techn...· 0 citations
A major focus of this review is antibody-drug conjugates (ADCs) targeting novel surface antigens, including HER2, HER3, and TROP2, which have demonstrated remarkable clinical efficacy in EGFR TKI-resistant settings.
Xin-Ran Chen, Jia-Qi Liang, Jun-Kan Zhu et al.· Biochimica et biophysica act...· 0 citations
Advances in targeted and immune-based therapies are transforming breast cancer care and Leveraging molecular insights, particularly for TNBC, is crucial to delivering personalised, clinically meaningful treatments and improving outcomes across all subtypes.
S. Sengupta, Ruhi Arisha, Kamal Shah et al.· Recent Patents on Anti-Cance...· 0 citations
The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.
P. Paliogiannis, G. Fara, A. Zinellu et al.· Current Issues in Molecular...· 0 citations
Currently, with the spectacular achievement of the tyrosine kinase inhibitors (TKIs), non-small cell lung cancer (NSCLC) carrying mutations of the gene epidermal growth factor receptor (EGFR) and rearrangements of the gene anaplastic lymphoma kinase (ALK) is becoming a paradigm of precision oncology. While there has be...
S. Dhillon, H. Rathod, Sagar Dhillon· Cureus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.